2. Academic Validation
  3. Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression

Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression

  • Mol Cancer. 2025 Dec 18;24(1):310. doi: 10.1186/s12943-025-02527-z.
Erik Rasbach # 1 2 3,  Laure Migayron # 1 2,  Anne Brandenburg # 1 4,  Praveen Singh 1 2,  Christina Martins 1 2,  Ali Kassem 3,  Anastasia I Karkempetzaki 1 2,  Nadine Suessner 3,  Zsofi Kulcsar 1 2 4,  Jessica Riopedre 1 2,  Mariana Silva 1,  Ethan Zhen 5,  Shuyun Xu 5,  Kyla Mucciarone 5,  Julia Holzgruber 1 2 6,  Jason B Williams 1,  Emrullah Birgin 3,  Mitchell P Levesque 7,  Julia M Martínez-Gómez 7,  Reinhard Dummer 7,  Jennifer Landsberg 4,  Christine G Lian 5,  George F Murphy 5,  Emma L Berdan 8,  Shannan Ho Sui 8,  Thomas S Kupper 1,  Nuh N Rahbari 3,  Nayoung Lee 1 9,  Steven R Barthel 10 11,  Tobias Schatton 12 13 14
Affiliations

Affiliations

  • 1 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • 2 Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • 3 Department of General and Visceral Surgery, Ulm University Medical Center, Ulm, 89081, Germany.
  • 4 Center for Skin Diseases, Clinic for Dermatooncology and Phlebology, University Hospital Bonn, Bonn, 53127, Germany.
  • 5 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • 6 Department of Dermatology and Venerology, Johannes Kepler University, Linz, 4020, Austria.
  • 7 Department of Dermatology, University of Zurich Hospital, University of Zurich, Schlieren, Switzerland.
  • 8 Department of Biostatistics, Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Harvard Medical School, Boston, MA, 02115, USA.
  • 9 The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NY, 10016, New York, USA.
  • 10 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. sbarthel@bwh.harvard.edu.
  • 11 Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. sbarthel@bwh.harvard.edu.
  • 12 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. tschatton@bwh.harvard.edu.
  • 13 Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. tschatton@bwh.harvard.edu.
  • 14 Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. tschatton@bwh.harvard.edu.
  • # Contributed equally.
PMID: 41413567 DOI: 10.1186/s12943-025-02527-z
Abstract

Background: ITGB2 is a critical Integrin mediator of immune cell activation and trafficking. Its expression has been claimed as exclusive to hematopoietic cells. Consequently, the significance of Cancer cell-intrinsic ITGB2 in solid tumor progression and therapy has not been rigorously evaluated.

Methods: We leveraged single-cell and bulk RNA Sequencing, real-time quantitative PCR, multiplex immunofluorescence, flow cytometry, immunoblotting, and intercellular adhesion molecule (ICAM)-1-dependent adhesion and proliferation assays to uncover melanoma cell-intrinsic ITGB2 functional expression, association with clinical tumor progression, activation, protumorigenic signaling, adhesive and proliferative functions utilizing patient melanoma biospecimens, established human and murine melanoma lines. In vivo tumorigenicity studies in immunocompromised NOD/SCID interleukin-2 receptor γ chain null (NSG), immunocompetent wildtype, and Icam1 knockout (KO) C57BL/6 mice were performed to dissect melanoma-ITGB2 downstream pathway activity and functions in tumor growth and metastasis. The Cancer cell-intrinsic ITGB2 axis was targeted using CRISPR/Cas9-based Itgb2 KO, blocking ITGB2 antibodies, ITGB2-activating CD44 crosslinking, and pharmacologic inhibition of ITGB2-dependent Wnt signaling using LGK974, zamaporvint, and FDA-approved pyrvinium pamoate repurposed for Cancer therapy.

Results: This work demonstrates nonhematopoietic expression and protumorigenic functions of ITGB2 intrinsic to melanoma cells. Tumor cell-ITGB2 mediated adhesion to ICAM-1, promoted Cancer progression in preclinical melanoma models, was enriched in clinical metastatic versus primary melanomas or benign nevi, and predicted sentinel lymph node metastasis in patients with primary disease. Consistently, inhibition of melanoma cell-intrinsic ITGB2 using blocking antibodies or Itgb2 gene KO potently suppressed ICAM-1-mediated melanoma cell adhesion, tumor growth, and metastatic dissemination. Melanoma cell-ITGB2:ICAM-1 interaction activated downstream Wnt signaling, the pharmacologic inhibition of which suppressed melanoma-ITGB2-mediated tumorigenesis.

Conclusions: This work overturns the longstanding paradigm that ITGB2 is restricted to leukocytes by discovering a tumor cell-intrinsic ITGB2:ICAM-1:Wnt protumorigenic axis as a bona fide Cancer therapeutic target in melanoma.

Keywords

CD18; CD44; ICAM-1; ITGB2; Integrin β2; Melanoma; Metastasis; Wnt.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z